Heterozygous Familial Hypercholesterolemia (HeFH) Latest Advances

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Journal: Journal of atherosclerosis and thrombosis

Published: October 08, 2025

Clinical features of familial hypercholesterolemia in children

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: September 17, 2025

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Journal: Cureus

Published: September 14, 2025

Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia.

Journal: Journal of clinical research in pediatric endocrinology

Published: August 28, 2025

Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.

Journal: Internal medicine (Tokyo, Japan)

Published: August 27, 2025

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Journal: Journal of the American Heart Association

Published: August 23, 2025

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.

Journal: The journal of prevention of Alzheimer's disease

Published: August 19, 2025

Polygenic Modulation of Monogenic Diseases: Familial Hypercholesterolemia as the Exemplar.

Journal: Current atherosclerosis reports

Published: July 30, 2025

Familial hypercholesterolemia caused by compound heterozygous variants in the LDLR gene: a case report

Journal: Zhonghua xin xue guan bing za zhi

Published: July 24, 2025

The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk.

Journal: Journal of cardiovascular development and disease

Published: July 01, 2025

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.

Journal: Journal of the American College of Cardiology

Published: June 30, 2025

HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol.

Journal: Endocrine

Published: June 30, 2025

Filters

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Clinical features of familial hypercholesterolemia in children

Clinical features of familial hypercholesterolemia in children

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia.

Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia.

Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.

Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.

Polygenic Modulation of Monogenic Diseases: Familial Hypercholesterolemia as the Exemplar.

Polygenic Modulation of Monogenic Diseases: Familial Hypercholesterolemia as the Exemplar.

Familial hypercholesterolemia caused by compound heterozygous variants in the LDLR gene: a case report

Familial hypercholesterolemia caused by compound heterozygous variants in the LDLR gene: a case report

The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk.

The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk.

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.

HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol.

HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous Familial hypercholesterolemia beyond LDL cholesterol.